Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104748 - 104748

Published: May 1, 2025

Precision medicine has revolutionized clinical paradigm of lung cancer (LC) patients optimizing therapeutical options on the basis molecular fingerprinting tumor cells. The advent genomic era contributed to widespread diffusion sequencing technologies laying for approval an increasing number clinically relevant predictive biomarkers in settings. In rapidly evolving scenario biomarkers, mandatory testing genes demonstrated a statistically significant benefit LC elected tests, but emerging are under investigation raise bar management patients. To date, promising IHC-based emerged as potentially integrative tools panel approved biomarkers. On this basis, genomic, transcriptomic and proteomic data gaining ground toward "3D" biology" supporting need multidimensional analysis cells stratify Here we sought overview most investigated trials be integrated into diagnostic NSCLC

Language: Английский